科華生物(002022.SZ):擬攜手聖湘生物共設湖南聖科生物技術有限公司
格隆匯11月8日丨科華生物(002022.SZ)公吿稱,作為免疫診斷領域中的新技術,化學發光免疫分析結合了化學發光的高靈敏度和免疫分析的高特異性,在臨牀檢驗、藥物分析、環境監測等領域得到了廣泛應用。隨着集採、DRGs帶來的檢測價格下降和居民高端檢測需求提升,化學發光診斷市場的需求將呈現明顯上升趨勢。
基於對該細分領域市場發展的長期看好,同時也為了推進公司與聖湘生物(688289.SH)在化學發光免疫細分領域展開合作,實現優勢互補、互利共贏,公司與聖湘生物簽訂了《投資框架意向書》。由公司與聖湘生物共同出資5000萬元,投資設立合資公司“湖南聖科生物技術有限公司(Sansure Immunotech)”(擬用名)。
合資公司以科華生物控股目標公司的形式設立,合資公司財務報表納入科華生物合併報表範圍。合資公司股權比例為:科華生物佔比50%,聖湘生物佔比50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.